Smith Asset Management Group LP decreased its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,380 shares of the biotechnology company’s stock after selling 1,200 shares during the period. Smith Asset Management Group LP’s holdings in Ironwood Pharmaceuticals were worth $517,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Strs Ohio raised its position in shares of Ironwood Pharmaceuticals by 132.1% in the first quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 3,700 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $192,000. Jane Street Group LLC acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $194,000. Karp Capital Management Corp acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $201,000. Finally, Raymond James Financial Services Advisors Inc. raised its position in shares of Ironwood Pharmaceuticals by 8.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 898 shares during the period. Institutional investors own 97.85% of the company’s stock.

Ironwood Pharmaceuticals, Inc. (IRWD) opened at 15.00 on Tuesday. The company has a 50-day moving average of $17.62 and a 200-day moving average of $17.18. Ironwood Pharmaceuticals, Inc. has a 1-year low of $12.48 and a 1-year high of $19.94. The firm’s market capitalization is $2.24 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The firm had revenue of $65.10 million for the quarter, compared to the consensus estimate of $70 million. During the same period last year, the company posted ($0.16) earnings per share. The business’s revenue was up 19.7% compared to the same quarter last year. On average, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post ($1.10) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Smith Asset Management Group LP Has $517,000 Stake in Ironwood Pharmaceuticals, Inc. (IRWD)” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/smith-asset-management-group-lp-has-517000-stake-in-ironwood-pharmaceuticals-inc-irwd/1489582.html.

Several research analysts have recently commented on the stock. Wedbush restated a “neutral” rating and set a $13.00 price target on shares of Ironwood Pharmaceuticals in a research note on Tuesday, May 9th. J P Morgan Chase & Co restated a “neutral” rating and set a $19.00 price target (down previously from $20.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, July 21st. BidaskClub lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Mizuho raised their target price on shares of Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. Finally, Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $18.50.

In other Ironwood Pharmaceuticals news, insider Halley E. Gilbert sold 35,000 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total transaction of $691,250.00. Following the sale, the insider now directly owns 35,000 shares of the company’s stock, valued at $691,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.63% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.